5 Factors to Consider When Recommending Farxiga© (dapagliflozin)

Farxiga© (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Dapagliflozin was recently approved for oral use as an adjunct to diet and exercise in the treatment of type 2 diabetes mellitus.

  1. There is evidence that dapagliflozin improves glycemic control in patients with type 2 diabetes mellitus whose diabetes is not controlled with metformin monotherapy.
  2. There is evidence that dapagliflozin and glipizide are equally effective when used as adjuvant therapy in patients with type 2 diabetes mellitus whose diabetes is not controlled with metformin monotherapy.
  3. The long term safety and effectiveness of dapagliflozin has not been assessed.
  4. Dapagliflozin has not been compared to other SGLT2 inhibitors.
  5. Only a few studies have compared dapagliflozin’s effectiveness to other classes of antidiabetics.

Adapted from a poster presentation by former Mercer University College of Pharmacy student Andy Tran. Click the following image for more information:

Andy Tran - Farxiga (final)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s